NeoGenomics, Inc.: valuation
What the market value assumes, and what the company's own statements and its peers' prices would put it at. Every assumption is yours to change.
Cash-flow value
Free cash flow over the last three years averaged below zero, so a cash-flow value cannot be worked out.
Your own DCF model
A full discounted-cash-flow model of NeoGenomics, Inc., started from its filings: revenue growth and margins year by year, bear, base and bull cases, the WACC and its parts, sensitivity tables and a value per share against the dated market price. Save it, share it with your team or by a read-only link.
Open the DCF modelAgainst the industry Diagnostics and Research
Multiples of its companies with a market value at most 60 days old, times NeoGenomics, Inc.'s own figures of FY2025.
| Multiple | Peers (25th / median / 75th) | NeoGenomics, Inc. | Applied to | Value (25th to 75th) | Companies |
|---|---|---|---|---|---|
| Price to sales | 2.3× / 5.4× / 8.1× | 2.8× | revenue $727 M | $1.7 B to $5.9 B | 36 |
| Price to book | 3.1× / 6.9× / 14.1× | 2.6× | book equity $837 M | $2.6 B to $11.8 B | 34 |
Against its own history
NeoGenomics, Inc.'s multiples at each month end with a market cap on file, Jan 2020 to Oct 2026, each against its own median.
Price to sales
2.9×Now above its median of 2.3×; range 1.0× to 14.6× over 30 months.
Price to book
2.6×Now above its median of 1.8×, in the top quarter of its range; range 0.7× to 11.8× over 30 months.
As of Oct 15, 2026
The statements it starts from
USD millions at each year's exchange rate; free cash flow = cash from operations less capital spending.
| Fiscal year | Revenue | Net income | Cash from operations | Capital spending | Free cash flow | Net debt | Source |
|---|---|---|---|---|---|---|---|
| FY2025to Dec 31, 2025 | $727 M | $-108 M | $5 M | $27 M | $-22 M | $182 M | SEC annual report (10-K, 20-F) |
| FY2024to Dec 31, 2024 | $661 M | $-79 M | $7 M | $41 M | $-34 M | $174 M | SEC annual report (10-K, 20-F) |
| FY2023to Dec 31, 2023 | $592 M | $-88 M | $-2 M | $29 M | $-31 M | $196 M | SEC annual report (10-K, 20-F) |
| FY2022to Dec 31, 2022 | $510 M | $-144 M | $-66 M | $31 M | $-97 M | — | SEC annual report (10-K, 20-F) |
| FY2021to Dec 31, 2021 | $484 M | $-8 M | $-27 M | $64 M | $-91 M | — | SEC annual report (10-K, 20-F) |
| FY2020to Dec 31, 2020 | $444 M | $4 M | $1 M | $29 M | $-28 M | — | SEC annual report (10-K, 20-F) |